Campus alert status is orange: For the latest campus alert status, news and resources, visit

Search Close Search
Search Close Search
Page Menu

Immune Disorders at UMMS.

Research topics on Immunology, Virology, Infectious Diseases, and Microbiology at UMMS includes:  

HIV, Numerous infectious diseases, autoimmune disorders, new antibacterial treatments and more. Browse our innovation by scrolling though below.  






Browse Our Inventions:



Title: Genetically Modified Non-Human Animals and Methods Relating to Complement Dependent Cytotoxicity. UMMS16-63; Patent Pending. 

  • The present invention provides a genetically modified immunodeficient mouse, wherein the genome of the mouse comprises a repaired C5 complement component structural gene such that the 5 genetically modified immunodeficient mouse expresses the C5 complement component structural gene and is characterized by an intact complement system. The present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/B1N, BlO.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice.

Title: Lanatoside C Inhibition of Zika Virus Infection. UMMS16-60; Patent Pending. 

  • This new discovery has found that cardiac glycoside Lanatoside C - an inhibitor of dengue virus, flavivirus Kunjin, alphavirus Chickingunya, and enterovirus 71 - also effectively stops replication of the Zika virus. This invention discloses treatment of Zika virus with Lanatoside C alone and in combination with ribavirin or ivermectin.

Title: Use of miR-122 to Treat Liver Diseases. UMMS16-56; Patent Pending.  

  • This invention builds on the new discovery that grainyhead-like 1 and 2 (GRHL-1 and -2) proteins inhibit tumor suppressor, microRNA-122 (miR-122). Increasing the bioavailability of miR-122 may potentially help to treat liver diseases such as steatosis, inflammation, fibrosis, and liver cancer such as hepatocellular carcinoma. Therapeutic inhibition GRHL-1&2 may restore the positive therapeutic effects of miR-122 in liver.

Title: Topical Application of Agents to Affect Neutrophil Migration Across Polarized Epithelial Barriers. UMMS16-46; Patent Pending.

  • A newly discovered efflux pump, MRP2, secretes lipids that attract neutrophils and initiate inflammation. Inhibition of MRP2 or inactivation of the secreted lipids can safely and effectively reduce inflammation at local tissues. This invention reduces inflammation by opposing the pro-inflammatory MRP2 system also by utilizing an endocannabinoid system that acts through the CB2 receptor. Increasing the activity of the CB2 endocannabinoid pathway can suppress local neutrophil migration consequentially result in anti-inflammation. 

Title: Anthelmintic Compositions and Methods. UMMS16-43; Patent Pending. 

  • This technology is based on the novel discovery that crystal proteins are highly potent anthelmintics. The invention comprises compositions and methods to treat a parasitic worm infection by administering to a subject a recombinant gram-positive bacterium expressing a crystal protein. The invention further discloses combination therapies wherein the recombinant bacteria is combined with a nicotinic acetylcholine receptor agonist.

Title: Systems and Methods for Monitoring, Managing, and Treating Asthma and Anaphylaxis. UMMS16-40; Patent Pending.  

  • The invention describes two devices that enable outpatient monitoring of asthma severity and anaphylaxis in real time. The first device is a wearable device that monitors breathing, assesses asthma severity, and alerts to dangerous changes. The second device is a wearable device that alerts upon early detection of anaphylaxis, auto-injects epinephrine, and calls emergency services (e.g., initiates 911 call) and/or family. Both technologies. 

Title: A New Generation of Antihelminthic Medications that Trigger Aberrant Immune Responses in Pathogenic Nematodes. UMMS16-25; Patent Pending. 

  • The present invention is related to the treatment and prevention of nematode infection in mammals. In general, the present invention provides small organic compounds and RNAi molecules targeting the p38 mitogen activated protein kinase pathway in xenobiotic-resistant nematodes. Further, the present invention combines an immunostimulatory small molecule with a pharmacologic inducer of an endoplasmic reticulum unfolded protein response to provide a synergistic therapy for human pathogenic nematode infection. 

Back To Top 




  • This invention discloses the first ever genetic screen to identify Hepatitis B virus host factors. The invention further encompasses the factors, such as Zinc finger, CCHC domain containing 14 (ZCCHC14), identified by those methods and methods of treating Hepatitis B virus infections by targeting those factors.

Title: Incorporation/Packaging Viral/Tumor Antigens in Virus-like Particle. UMMS15-47; Patent Pending.

  • The invention relates to a vaccine for Eptein Barr Virus. The prophylactic is a recombinant virus-like particle (VLP) comprising a Newcastle disease virus (NDV) matrix (M) protein, a NDV nucleocapsid (NP) protein, and one or more tumor-associated EBV antigens that is capable of illiciting CD4+ and CD8+ T cell responses. 

Title: Factor H/Fc Chimeric Molecules as Anti-pathogen Immunoadhesins. UMMS15-30, Patent Pending.  

  • A novel immunotherapeutic approach against drug-resistant pathogens, such as Neisseria gonorrhoeae, comprising administration to a subject a fusion protein linking Factor H to IgG Fc. 

Title: Development of Efficient and Safe rAAV Compatible Silencing Construct. UMMS 15-29; Patent Pending. 

  • This invention spans from the invention of UMMS15-28, an rAAV optimized for compatibility and efficacy for shRNA delivery. This process was tested in UMMS15-28 by examining the regional importance of shRNA within the viral genome. This upgraded shRNA-rAAV delivery system has optimized flanking sequences and shRNA structure. The shRNA backbone has lower loop complementarity, causing lower thermodynamic stability that increases its efficacy. This concept was tested by designing multiple Artificial miRNA (AmiRNA), where AmiRNA have the optimized structure while still possessing the shRNA interfering properties. This mechanism for shRNA deliver is highly efficient and safe for sustained silencing. 

Title: Novel rAAV Genome Designs Using Artificial Hairpin Loop Structures to Replace at least One AAV Inverted Terminal Repeat (ITR). UMMS 15-28; Patent Pending. 

  • This invention capitalizes on the discovery that short hairpin RNA (shRNA) can hinder viral genome replication when specifically placed in relationship to the AAV ITR. To improve the efficacy of AAV-mediated shRNA delivery, the inventors designed and tested multiple rAAV with shRNA placed in different regions of the AAV genome in order to identify the optimal AAV vector for shRNA. 

Title: Tet1-Dependent Differentiation of Human Hematopoietic Stem Cell towards NKT And γδ T Cells. UMMS15-18; Patent Pending. 

  • The invention provides methods of producing hematopoietic stem cells (HSCs) with increased differentiation towards natural killer T cells (NKT) and gamma delta T cells (γδ T cells) for cancer immunotherapy. The HSCs are also functionally superior in their capacity to kill tumor cells, as injection of HSCs overexpressing Tet1 eliminates all of the carcinoma stages of neoplasia. 

Title: Creation of RIPK3 Reporter and Conditional Deletion Mouse Model. UMMS15-05; Patent Pending. 

  • This invention allows investigators to track endogenous RIPK3 expression in live cells and enables tissue-specific inactivation of RIPK3.  Specifically, the last coding exon of the mouse RIPK3 gene is fused in-frame to the enhanced green fluorescent protein (GFP). LoxP sites flank the last coding exon of RIPK3. Crossing the RIPK3-GFP “floxed” mice to transgenic mice expressing Cre recombinase under the control of tissue-specific promoter enables conditional deletion and inactivation of RIPK3 in distinct tissues. 

Title: Broadly Borreliacidal Human Monoclonal Antibodies to OspA and their Uses. UMMS15-03; Patent Pending. 

Back To Top 




  • Invention encompasses a new strategy to combat drug-resistant gonorrhea. This technology manipulates the lipooligosacchride capping of gonococci, thereby decreasing it’s fitness and virulence. By interrupting the sialic acid mediated pathogenesis that contributes to drug-resistance, this intervention can render gonorrhoeae sensitive to killing by the innate immunity system. 

Title: Dual Specific Binding Proteins Directed Against Immune Cell Receptors and Autoantigens. UMMS14-75; Patent Pending. 

  • To address the need for improved multivalent binding proteins capable of binding immune cell receptors and autoantigens, this novel invention provides bispecific binding proteins that bind to two targets: (1) a TLR-activating autoantigen and (2) an immune cell receptor (e.g., the B cell receptor) thereby forming an immune complex that is internalized and transported to TLRs resident in the endosomal compartment. The bispecific binding proteins are useful as a vehicle for the modulation of endosomal TLR signaling, and, hence, modulation of autoimmune disease. 

Title: Conditional ASC-citrine Expressing Inflammasome Reporter Mouse. UMMS14-64. Related Publication.

  • To facilitate the study of inflammasome activation in vivo, this transgenic mouse expresses fluorescent ASC in the Rosa26 locus. This system contains a knock-in of ASC-citrine gene and a proximal floxed stop site enabling conditional expression in a lineage specific manner by breeding mice with different cre expressing lines. 

Title: Human Antibodies Against Rabies and Uses Thereof. UMMS14-48; Patent Pending. 

Title: REBISS Score and REBISS Score Calculator. UMMS14-32; Patent Pending. 

  • To prevent misdiagnosis, this technology discloses a clinical scoring system that effectively and efficiently utilizes a number of different data sources to determine a diagnosis of patient conditions. The score is compared to a spectrum of scores in order to identify between disorders, such as Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBSd) or gastroesophageal reflux disease (GERD) and functional dyspepsia for which there are currently no validated scoring systems. 

Title: Mitogen-Activated Protein Kinase Kinase Kinase Kinase (Map4k4) as a Therapeutic Target of Muscular Dystrophies including Duchenne Muscular Dystrophy (DMD). UMMS12-29; Patent Pending. 

  • The technology provides novels compositions and methods for treating muscle disorders comprising administration of inhibitory oligonucleotides and ribozymes that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) in myoblasts or myocytes. Futher provided are methods of using oligonucleotides targeting Map4k4 to induce differentiation of the myoblast to a mature myocyte that can be used as a research tool to identify therapeutic agents. 

Title: miRNA-mediated Transcriptional Detargeting to Reduce Transgene Immunity. UMMS14-22; Patent Pending.

  • This new AAV technology involves co-delivery of a transgene that minimizes immune responses against the transgene product of interest. Specifically, this process involves administering a rAA-harboring a transgene engineered to express an inhibitory RNA transcript that targets one or more immune- associated miRNA. This interaction lowers the immune response and consequently increases the potency of the therapeutic protein and its effects. 

Back To Top



Title: Anti-fracCRP Hybridomas and Monoclonal Antibodies. UMMS13-71; Patent Pending.  

  • This invention provides antibodies and antibody fragments that bind to human fractional C-Reactive Protein (fracCRP), kits and assays using these antibodies and antibody fragments to diagnose low to moderate risk for Acute Coronary Syndrome (ACS). This invention is based on two clinical studies (one prospective, one retrospective) that measured fracCRP, Troponin I (TnI), and the fracCRPxTnI metric on 210 patients (105 each with final diagnoses of ACS negative or ACS positive). Overall, the method demonstrated strong diagnostic rule-in value for these patients on arrival, with a specificity of 96.2%, positive predictive value of 91.7%, sensitivity of 41.9%, and negative predictive value of 62.3%. 

Title: BCR Adapter lgM (BCRAM) for the BCR/TLR Delivery of Autoantigens to Polyclonal Murine and Human B Cell Populations. UMMS13-65; Patent Pending.

  • This technology provides a model for autoantigen activation of B cells that can be used to research and treat the development/progression of autoimmune diseases, such as systemic lupus erythematosus (SLE).  This novel research tool enables the identification of suitable drug targets and provides methods for production of autoantigens.  Specifically, a BCR adapter IgM (BCRAM) is described to exemplify delivery of autoantigens to polyclonal B cell populations resulting in immunoactivation by Toll-like receptor activation. 

Title: Compositions and Methods for Recruitment and Activation of Macrophages in Injured Tissues and in Implanted Biomaterials Used for Tissue Engineering. UMMS13-62; Patent Pending. 

  • The present invention is related to the field of wound healing and regeneration and repair of injured internal tissues and tissue engineering by synthetic implants and implants of natural origin. In particular, the present invention provides compositions and methods comprising molecules (such as nanoparticles) with linked α-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue, and rapid localized recruitment and activation of macrophages that promote regeneration and repair of a wide variety of internal tissues and organs injured as a result of various types of trauma as well as of tissues and organs treated with biomaterials.

Title: Development of NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl> Tlr4lps-del Sz/Sz ("NSG Tlr4 Mice"). UMMS13-61. 

  • This invention provides a immunodeficient mouse model based on the NOD strain (referred to as NSG and NRG mice) that can be engrafted with functional human immune systems, including adaptive and innate immune systems. These mice completely lack adaptive immune cells such as T and B cells, as well as NK cells.  To study the response of human innate immune cells to the TLR agonist LPS in the absence of a murine innate immune response, these NSG mice completely lack TLR4 on their innate immune cells. 


  • The invention provides codon-optimized DNA's and polypeptides useful for inducing an immune response against HIV.  The compositions and methods provided are based on the discovery that specific polyvalent, primary isolate DNA vaccines can effectively induce an immune response against HIV (e.g., HIV-1), e.g., alone or in combination with boosts of recombinant HIV polypeptide compositions. 


  • The present technology relates to the treatment or prevention of infection, by administration of a liposome composition linked to binding targets. The compositions typically bind the virus (or virions), e.g., influenza, or bacteria, e.g., Streptococcus pneumonia, with high affinity to reduce or prevent infectivity. The technology is used to reduce or prevent the effects of a toxin, e.g., ricin, with high affinity to reduce or prevent toxin entry into a cell. Further, this invention discloses sulfated polysaccharides and sulfated polysaccharide compositions, which can prevent or treat viral infection, specifically respiratory syncytial virus (RSV).

Title: Peptide-modified Glucagon Particles for Delivery of Therapeutic Cargoes. UMMS13-05; Patent Pending. 

  • This technology embodies a novel delivery vehicle for RNAi, particularly amenable to therapeutic targeting of gut inflammatory cytokines via oral administration. The invention discloses amine conjugated glucan particles, extracted from yeast cell walls, for the delivery of nucleic acid cargoes. 

Back To Top




  • The invention provides novel surface coatings for metallic implants to prevent periprosthetic infections after orthopedic surgery. To achieve optimal anti-fouling and bactericidial effects of commercial metallic implants, the invention has surface polymer brushes with tightly controlled yet tunable molecular weights (thickness of coating), low-fouling side chain densities and the conformational freedom needed to be grafted from the surface. By employing significantly improved surface-initiated polymerization of low-fouling, zwitterionic polymer brushes and higher-density covalent presentation of antibiotics (e.g. vancomycin) anti-infection outcomes are optimized. 


  • The technology provides novels compositions and methods for treating muscle disorders comprising administration of inhibitory oligonucleotides and ribozymes that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) in myoblasts or myocytes. Futher provided are methods of using oligonucleotides targeting Map4k4 to induce differentiation of the myoblast to a mature myocyte that can be used as a research tool to identify therapeutic agents.

Title: An IFNβ Reporter Cell Line, clone SZ34. UMMS12-01. 

  • Large-scale and high throughput screen for compounds that module type I interferons identify potential therapeutics that block viral replication. Clone SZ34 is a stabilly transfected human embryonic kidney cell (HEK) with expression plasmids for an IFN-Beta-promoter-driven firefly luciferase reporter gene (IFN-Beta-Luc). 

Back To Top




  • This patented technology provides prophylactic DNA constructs that encode a recombinant HIV-1 gp120 envelope peptide, in which either the V1/V2 loop and the V4 loop, or all three variable loops, including V3, are replaced with a V3 sequence each of which is from a different viral isolate. These constructs generate a more broadly reactive neutralizing antibody than conventional gp120 or V3 DNA or polypeptide immunogens. 

Back To Top




  • This invention discloses antibodies that bind to human fractional C-Reactive Protein (fracCRP), kits containing these antibodies and antibody fragments, and assays using these antibodies and antibody fragments to assess patients at low to moderate risk for Acute Coronary Syndrome (ACS). Overall, this method demonstrated strong diagnostic rule-in value for these patients, with a specificity of 96.2%, positive predictive value of 91.7%, sensitivity of 41.9%, and negative predictive value of 62.3%. 

Title: Transgenic Non-Human Animal and Methods for Stem Cell Engraftment. UMMS10-43; Patent Pending.  

  • A transgenic immunodeficient non-obese diabetic (NOD) mouse homozygous for the SCID mutation and having an IL2 receptor gamma chain deficiency. Administration of human stem cells to the mouse in the absence of conditioning by irradiation results in similar or greater levels of engraftment of human stem cells compared to a non-obese diabetic (NOD) mouse homozygous. 

Title: A New Approach to Accelerate Antibiotic Action. UMMS10-30; Patent Pending.

  • This is a novel method to increase the efficacy of antibiotics by targeting bacterial central metabolism. The UMass Medical School inventors identified 38 metabolic targets, inhibition of which with concurrent antibiotic treatment can synergistically kill slow-growing dormant Mycobacterium tuberculosis (Mtb), the agent of human tuberculosis. These slow-growing bacterial populations are challenging to eradicate because they are refractory to antibiotic treatment. Inhibiting Mtb central metabolism enables more thorough treatment of tuberculosis infection and may be applicable to other infectious diseases.

Title: Immunotherapy for T Cell-Mediated Autoimmune Diseases Using ITK Inhibitors. UMMS10-05; Patent Pending. 

  • The present disclosure is based, in part, on the discovery that interleukin-2-inducible T cell kinase (ITK) and CD28 signals regulate auto-reactive T cell trafficking and that organ-specific T cell mediated autoimmune diseases such as Type 1 diabetes and multiple sclerosis. Accordingly, the present specification provides methods of treating organ-specific T cell mediated autoimmune diseases by inhibiting ITK with a therapeutically effective amount of an ITK inhibitor, e.g., BMS509744, ibrutinib, 10n, 2-amino-5-(thioaryl)thiazole, 5 aminomethylbenzimidazole, 2-amino-5-[(thiomethyparyl]thiazole, and biaryl thiophene. 


  • The present invention relates to peptide mimics of a conserved gonococcal lipo-oligosaccharide (LOS) epitope of Neisseria gonorrhoeae, which epitope is not found on human blood group antigens. This invention also relates to methods and compositions using such peptide mimics for the prophylaxis of gonorrheal infections. 


Back To Top




  • This invention discloses methods and compositions to detect Toll-like receptor (TLR) binding to ligands and evaluate compound for screening. Using different biosensor complexes, this technology enables the diagnosis of gram positive or negative infections in a human subject. Each platform utilizes a TLR conjugated to a biosensor that detects a single TLR-ligand binding domain complementary to its cognate ligand. This technology can provide a method to select appropriate treatment for a patient with inflammatory and possibly other conditions.

Title: COMPOUNDS FOR MODULATING TLR2. UMMS09-52 Patent 8,609,6639,271,972.

  • Viral infection causes damage to the host via stimulation of production of host cytokines. These processes can culminate in edema and damage to host organs. From screening, this novel invention identifies molecules that could potentially inhibit the cytokine response to viral infection by inhibiting RNA virus-mediated TNF-alpha production. The current invention discloses methods of the system used to screen, a TLR2 and CD14 stable cell line, and molecular inhibitors of Lymphocytic Choriomeningitis Virus (LCMV) induced cytokine production. These newly discovered molecules may facilitate amelioration of symptoms in a broad range of hemorrhagic fever viruses.



  • This patented invention provides methods for detecting the presence of replication-competent HIV-1 virus in a subject who is being treated with an intensified highly active anti-retroviral therapy (HAART) regimen. These methods comprise obtaining a blood sample, specifically amplifying a segment spanning two-long terminal repeat (2-LTR) junction of 2-LTR circles using PCR and determining the presence of replication competent virus based on the level of 2-LTR circles in the sample. These methods can be used to monitor an intensified HAART regimen by obtaining samples from the same subject at different time points during the HAART treatment, and comparing levels of the 2-LTR circles in those samples.


  • This patented invention provides methods of attenuating HCMV replication by modulating miR145 and targets thereof. Also provided are methods of detecting an HCMV infection, and compositions and kits useful for attenuating HCMV replication.



  •  This patented invention provides a low risk, highly effective paramyxovirus vaccine that is compatible with population-wide distribution marketing goals of low cost and high production rates. The disclosed vaccine contains a virus-like particle (VLP) comprising a) Newcastle disease virus matrix (M) protein, b) Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein transmembrane domain (TM) protein, c) Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein cytoplasmic domain (CT) protein, and d) Respiratory Syncytial Virus (RSV) ectodomain protein, wherein said transmembrane (TM) protein is flanked by said cytoplasmic domain (CT) protein and said ectodomain protein.


  • This invention discloses an assay method for detecting anti-Neisseria antibodies. Human factor H (fH) is a virulence factor that helps Neisseria to resist complement-mediated killing, thus circumventing the host’s innate immune response. Higher serum fH levels may correlate to patient susceptibility to infection. Neisserial factor H binding protein (fHBp) can be hindered by a human amino acid sequence revealed in the present technology, to facilitate accurate detection of Neisseria that exceeds the capability of existing methods. A reaction mixture containing bactericidal anti-Neisseria antibodies, a fH polypeptide comprising an amino acid sequence of human Short Consensus Repeat 6 sources of non human complement (SCR), and a Neisseria bacterium. This invention additionally discloses an animal model of Neisseria infection.

Title: INTRACELLULAR DNA RECEPTORUMMS09-11; Patent 8,334,101.

  • The innate immune system recognizes non-self genetic material and mounts a defensive immune response. However, self cytosolic DNA at times gets targeted and the process by which this phenomenon occurs has been largely unknown. The inventors have discovered PISA (PYHIN protein stimulating ASC), a receptor found to be necessary for activation of the ACS/caspase-1 axis of innate immunity in response to recognition of self cytosolic DNA. This invention discloses methods for identification and compounds found to modulate the PISA receptor and it’s downstream immune response.


  • This invention reports the discovery of serum IgG of different individuals that block antibody (Ab) activity targeted against Neisseria membrane lipoprotein H.8. Blocking Ab activity may predispose such individuals to developing invasive disease with N. meningtitidis or decrease the efficacy of vaccines. This finding can explain the variability between individual susceptibility and provide new avenue for treatment and increasing efficacy of existing treatments.


  • This invention discloses a sequence of efficient cleavage point of F protein, of the respiratory syncytial virus (RSV) that causes infection. The cDNA has an optimized codon of F protein, which may be useful for developing a more effective RSV vaccine.

Back To Top



Title: Co-evolved Protease Substrate Cleavage Site Mutations Enhance Protease Inhibitor Resistance. UMMS08-59; Patent Pending.  

  • This new invention predicates on the finding that drug resistance in HIV arises from evolution of HIV proteases and it’s associated substrates, and discloses mutation patterns of both proteases and substrates that can be used to predict the efficacy of particular therapy in HIV patients. Understanding these mutational combinations will greatly change the approach to optimizing a patient-centered approach to managing HIV therapy. 

Title: Use of Cathepsin B Inhibitors for the Treatment of IL-1 Related Diseases. UMMS08-51; Patent Pending.  

  • This innovation describes detailed mechanisms of how immune cells recognize microorganisms (non-self) from host (self). The cytoplasmic receptor complex NALP3 inflammasome has been found to react to a variety of crystals such as silica crystals or cholesterol crystals, all of which were found to require phagocytosis for activation. By inhibiting phagosomal acidification, the inventors were able to prevent activation of NALP3 in the presence of the crystal activators. Understanding these mechanisms may be valuable to research into IL-1 related diseases of sterile inflammation including atherlosclerosis, amyloidosis, Alzheimer silicosis, asbestosis and others. 

Title: HIV-1 Protease Inhibitors: Part 6. UMMS08-41.

  • This invention provides new therapeutic agents to treat HIV using protease inhibitors that are less prone to resistance stemming from drug resistant mutations. Using computational and organic chemistry techniques, the inventors designed these new molecules by carefully considering nature of the HIV protease and it’s ability to detect substrates. This invention contains several sets of HIV protease inhibitors and unique drug combinations that have not yet been previously tested. 

Title: Detection of Human Immunodeficiency Virus. UMMS08-36; Patent Pending. 

  • This new PCR based assay can detect cells that have been recently infected by HIV, even those that may not typically be detectable while the patient is under aggressive antiretroviral therapy. In peripheral blood lymphocytes, this method detects circular viral DNA in individuals infected with HIV. This detection method has been found effective even when plasma viral RNA levels are undetectable under conventional HIV RNA-PCR testing. Research on this method also revealed that the currently implemented treatment with antiretroviral agents does not completely abolish the viral infection, providing an opportunity for further innovation in HIV management. 

Title: Monoclonal Antibody Producing Cell Lines called 2C3-like Cell Lines and the 2C3-like Antibodies that They Produce. UMMS08-34; Patent Pending.

  • This new invention spans from the discovery of novel antibodies and an antigen binding fragment that bind surface membrane proteins of Neisseria species (e.g. N. gonorrhoeae and N. meningitidis). This invention can be applied to diagnostic, therapeutic, and potentially preventative methods for managing Neisseria infections. 


  • This innovation provides a method to assess acute tissue damage and stratify acute coronary syndrome. Analysis of circulating C-reactive protein (CRP) and fractional forms of CRP (fracCRP), permits early measurement of tissue damage than fracCRP values only in a specific diseases context previous inventions, thus, broadening the scope of application for this established laboratory value.  of the use of fraCRP values. This process provides a method for a more comprehensive analysis of acute tissue damage that may be applicable to a variety of clinical scenarios.

Title: sST2 Dengue Virus Diagnostic. UMMS08-12; Patent Pending.

  • This invention uses interleukin-receptor like 1 protein (sST2) level to diagnose Dengue fever, infection with Dengue virus. Clinical symptoms of dengue infection are difficult to recognize and most individuals are asymptomatic or have only mild fever. This new technology addresses the need for a more effective diagnostic tool, capitalizing on the understanding that sST2 levels are elevated with in dengue virus infection when compared to uninfected patients. sST2 is further elevated during secondary infection, so this marker may serve to identify severity of infection. 

Title: Use of TRAIL Protein as Antiviral Agent. UMMS08-01; Patent Pending. 

  • This new invention discloses an antiviral molecule, TRAIL, which reduces cellular antiviral effects, and may provide an opportunity for treatment of RNA virus infection.  Blocking of TRAIL significantly reduces cellular antiviral effects, thus the invention proposes the use of TRAIL as therapy to reduce viral burden.